2019
Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial
Abdallah CG, Roache JD, Averill LA, Young-McCaughan S, Martini B, Gueorguieva R, Amoroso T, Southwick SM, Guthmiller K, López-Roca AL, Lautenschlager K, Mintz J, Litz BT, Williamson DE, Keane TM, Peterson AL, Krystal JH, PTSD F. Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. Contemporary Clinical Trials 2019, 81: 11-18. PMID: 30999057, DOI: 10.1016/j.cct.2019.04.009.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderStudy drugClinical trialsTherapeutic effectPharmacotherapy of PTSDFirst placebo-controlled trialPlacebo-controlled clinical trialActive duty military populationDose-related efficacyMedication treatment optionsPlacebo-controlled trialDose-related effectsNovel neural mechanismActive duty militaryKetamine infusionSerotonergic antidepressantsEligible participantsTreatment optionsCase reportNew drug developmentOnly trialSustained reductionVeteran populationDrug AdministrationPilot evidence
2011
Advancing drug discovery for schizophrenia
Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, Law AJ, Campbell B, Krystal JH, Moghaddam B, Saw A, Caron MG, George SR, Allen JA, Solis M. Advancing drug discovery for schizophrenia. Annals Of The New York Academy Of Sciences 2011, 1236: 30-43. PMID: 22032400, PMCID: PMC3787879, DOI: 10.1111/j.1749-6632.2011.06216.x.Peer-Reviewed Original Research
2004
Move Over ANOVA: Progress in Analyzing Repeated-Measures Data andIts Reflection in Papers Published in the Archives of General Psychiatry
Gueorguieva R, Krystal JH. Move Over ANOVA: Progress in Analyzing Repeated-Measures Data andIts Reflection in Papers Published in the Archives of General Psychiatry. JAMA Psychiatry 2004, 61: 310-317. PMID: 14993119, DOI: 10.1001/archpsyc.61.3.310.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceEndpoint DeterminationHumansModels, StatisticalPsychiatryResearch Design
2003
Treatment Models and Designs for Intervention Research During the Psychotic Prodrome
Kane JM, Krystal J, Correll CU. Treatment Models and Designs for Intervention Research During the Psychotic Prodrome. Schizophrenia Bulletin 2003, 29: 747-756. PMID: 14989412, DOI: 10.1093/oxfordjournals.schbul.a007044.Peer-Reviewed Original ResearchConceptsPsychotic prodromePsychotic disordersEarly interventionSubsequent symptom severityTreatment modelOngoing intervention trialsSpecific symptom clustersTreatment refractorinessFunctional disabilityPatient selectionIntervention trialsFunctional outcomeProdromal symptomsDisease progressionNatural courseTarget symptomsSubsyndromal symptomsDifferent treatment modelsOutcome measuresProdromal populationTreatment responseProdromal stateTrial designSymptom clustersSymptom severity
1999
Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion
Bunney W, Azarnoff D, Brown B, Cancro R, Gibbons R, Gillin J, Hullett S, Killam K, Kupfer D, Krystal J, Stolley P, French G, Pope A. Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. JAMA Psychiatry 1999, 56: 349-352. PMID: 10197830, DOI: 10.1001/archpsyc.56.4.349.Peer-Reviewed Original ResearchAdverse Drug Reaction Reporting SystemsChronic DiseaseDrug ApprovalDrug EvaluationEvaluation Studies as TopicHumansHypnotics and SedativesNational Academies of Science, Engineering, and Medicine, U.S., Health and Medicine DivisionPrevalenceProduct Surveillance, PostmarketingProfessional Staff CommitteesRandomized Controlled Trials as TopicResearch DesignSleep Initiation and Maintenance DisordersTriazolamUnited StatesUnited States Food and Drug Administration